FindTrial
Sign In

Effect of the use of guarana powder (Paullinia cupana) on the modulation of blood markers and mood in young adults

Effect of the use of guarana powder (Paullinia cupana) on the modulation of brain-derived neurotrophic factor and depressive symptoms in young adults

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-47jxgzv
Enrollment
Unknown
Registered
2022-04-27
Start date
2022-05-16
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depressive symptoms

Interventions

Experimental group will be composed of 50 adults of both sexes, non-obese and non-depressed, will receive guarana powder capsules (3g of guarana powder), while the control group will be composed of 50
G07.203.300
G07.203.300.456

Sponsors

Faculdade de Saúde Pública da Universidade de São Paulo - FSP/USP
Lead Sponsor
Faculdade de Saúde Pública da Universidade de São Paulo - FSP/USP
Collaborator

Eligibility

Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Young adult individuals (18 to 40 years old); Body mass index (between 18.5 and 29.99 kg/m2); Be willing to adhere to the study protocol; Be willing to sign the informed consent form (ICF)

Exclusion criteria

Exclusion criteria: Age under 18 and over 40; BMI greater than 29.99 Kg / m²;Having depression, hypertension and / or insomnia; Make use of medication prescribed to control anxiety, depression or other psychiatric disorder; Be a regular consumer of guarana, consumption of coffee, teas or energy drinks more tha 3 doses/day, as adopted in the study by Dood et al. (2015); Being pregnant or nursing; Be participating in another study

Design outcomes

Primary

MeasureTime frame
It is expected to find a modulation in the plasma content of brain-derived neurotrophic factor (BDNF) in eight weeks by means of enzyme-linked immunosorbent assay (ELISA), reverse transcription followed by real-time polymerase chain reaction (RT-PCR) and western blot, based on the finding of a variation of at least 30% in pre- and post-intervention measurements.—

Secondary

MeasureTime frame
Attenuation of inflammatory biomarkers in eight weeks, by means of an enzyme-linked immunosorbent assay (ELISA) based on the finding of a variation of at least 5% in pre- and post-intervention measurements.;Decrease in the score of depressive symptoms in eight weeks, through the application of the Beck Depression Inventory, based on the finding of a variation of at least 5% in the pre- and post-intervention measurements.—

Countries

Brazil

Contacts

Public ContactLeonardo Negrão

Faculdade de Saúde Pública da Universidade de São Paulo - FSP/USP

lnegrao@usp.br+55(11)3061-7748

Outcome results

None listed

Source: REBEC (via WHO ICTRP)